Skip to content

The efficacy and safety of green tea consumption after colon surgery: A randomized controlled trial

The efficacy and safety of green tea consumption after colon surgery: A randomized controlled trial - Postoperative green tea trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000048174
Enrollment
30
Registered
2022-06-27
Start date
2022-06-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon cancer

Interventions

Postoperative green tea 600ml per day Period: from postoperative 1 day to the time to first defication Postoperative water 600ml per day Period: from postoperative 1 day to the time to first deficat

Sponsors

Tochigi Medical Center Shimotsuga
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adults (male and female) aged more than 18 years olds 2. Participants with colon cancer

Exclusion criteria

Exclusion criteria: 1. Participants who are unable to provide informed consent or comply with research protocols 2. Participants who are known to have problems with mental health or language ability 3. Participants who are participating in other interventional trials 4. Emergency surgery 5. Multiple organ resection at the time of surgery 6. Extension or closure of an enterostomy at the time of surgery 7. Participants undergoing colostomy or ileostomy 8. Complete obstruction 9. Hypersensitivity or allergy to caffeine or green tea 10. American Society of Anesthesiologists (ASA) IV or V physical status score 11. Alcoholism or drug abuse 12. Regular intake of more than 800 mg of caffeine (8-10 cups of coffee) per day 13. Previous extensive abdominal surgery (excluding appendicectomy, cholecystectomy, hernia repair, or cesarean section) 14. Grade III or higher heart failure (NYHA) 15. Opioid analgesics or steroids greater than 5 mg/day for at least 7 days prior to surgery 16. Long-term use of glucocorticoids or stimulant laxatives 17. Taking antidepressants 18. Severe obesity (BMI > 32) and severe malnutrition (BMI < 15) 19. Hypertensive emergencies (>180/120 mmHg) 20. Pregnancy, lactation, or possible childbirth 21. Liver failure and/or cirrhosis (MELD > 15) 22. Drugs that are substrates or inhibitors of CYP1A2 enzymes (e.g., new quinolone antibacterial agents)

Design outcomes

Primary

MeasureTime frame
Time to first defecation (hours) Definition: time from the end of surgery to first defecation (hours) Period: from surgery to the first defecation

Secondary

MeasureTime frame
1. Length of hospital stay (days) Definition: Days from operation to discharge Period: from operation to discharge 2. Postoperative ileus Definition: the number of patients who had postoperative ileus described as a narrow-mindedness to oral nourishment without clinical or radiological indications of obstruction, that either 1) requires nasogastric tube insertion; or b) was related with two of the accompanying: nausea/vomiting, stomach distension, and the nonattendance of flatus hours on or after postoperative day two, divided by total patients in each group Period: within postoperative 30 days 3. Postoperative complications Definition: the number of patients with postoperative complications based on Clavien-Dindo classification of more than 2. Period: within postoperative 30 days. 4. the amount of drinking (ml) Definition: the mean amount of drinking per day (ml) Period: from surgery to the first defecation 5. All adverse events

Countries

Japan

Contacts

Public ContactJun Watanabe

Tochigi Medical Center Shimotsuga Surgery

m06105jw@jichi.ac.jp0282-22-2551

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026